<![CDATA[Dermatology Times 2025 Year in Review: Vitiligo]]>
In 2025, regulatory activity in vitiligo remained largely focused on optimizing use and broadening access to existing therapies while preparing for potential new systemic options. Ruxolitinib cream remains the only FDA–approved therapy specifically …